|
1
|
Knudsen ES, Gopal P and Singal AG: The
changing landscape of hepatocellular carcinoma: Etiology, genetics
and therapy. Am J Pathol. 184:574–583. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ahn J and Flamm SL: Hepatocellular
carcinoma. Dis Mon. 50:556–573. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Everson GT: Increasing incidence and
pretransplantation screening of hepatocellular carcinoma. Liver
Transpl. 6 (6 Suppl 2):S2–S10. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bruix J and Llovet JM: Major achievements
in hepatocellular carcinoma. Lancet. 373:614–616. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Olsen SK, Brown RS and Siegel AB:
Hepatocellular carcinoma: Review of current treatment with a focus
on targeted molecular therapies. Therap Adv Gastroenterol. 3:55–66.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Forner A and Bruix J: Biomarkers for early
diagnosis of hepatocellular carcinoma. Lancet Oncol. 13:750–751.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meseure D, Alsibai Drak K, Nicolas A,
Bieche I and Morillon A: Long noncoding RNAs as new architects in
cancer epigenetics, prognostic biomarkers, and potential
therapeutic targets. Biomed Res Int. 2015:3202142015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsai MC, Spitale RC and Chang HY: Long
intergenic noncoding RNAs: New links in cancer progression. Cancer
Res. 71:3–7. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wapinski O and Chang HY: Long noncoding
RNAs and human disease. Trends Cell Biol. 21:354–361. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Spizzo R, Almeida MI, Colombatti A and
Calin GA: Long non-coding RNAs and cancer: A new frontier of
translational research? Oncogene. 31:4577–4587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Flockhart RJ, Webster DE, Qu K,
Mascarenhas N, Kovalski J, Kretz M and Khavari PA: BRAFV600E
remodels the melanocyte transcriptome and induces BANCR to regulate
melanoma cell migration. Genome Res. 22:1006–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
McCarthy N: Epigenetics. Going places with
BANCR. Nat Rev Cancer. 12:4512012. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang ZX, Liu ZQ, Jiang B, Lu XY, Ning XF,
Yuan CT and Wang AL: BRAF activated non-coding RNA (BANCR)
promoting gastric cancer cells proliferation via regulation of
NF-κB1. Biochem Biophys Res Commun. 465:225–231. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zheng H, Wang M, Jiang L, Chu H, Hu J,
Ning J, Li B, Wang D and Xu J: BRAF-activated long non-coding RNA
modulates papillary thyroid carcinoma cell proliferation through
regulating thyroid stimulating hormone receptor. Cancer Res Treat.
48:698–707. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shi Y, Liu Y, Wang J, Jie D, Yun T, Li W,
Yan L, Wang K and Feng J: Downregulated long noncoding RNA BANCR
promotes the proliferation of colorectal cancer cells via
downregulation of p21 expression. PLoS One. 10:e01226792015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su S, Gao J, Wang T, Wang J, Li H and Wang
Z: Long non-coding RNA BANCR regulates growth and metastasis and is
associated with poor prognosis in retinoblastoma. Tumour Biol.
36:7205–7211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Y, Guo Q, Zhao Y, Chen J, Wang S, Hu
J and Sun Y: BRAF-activated long non-coding RNA contributes to cell
proliferation and activates autophagy in papillary thyroid
carcinoma. Oncol Lett. 8:1947–1952. 2014.PubMed/NCBI
|
|
19
|
Sun M, Liu XH, Wang KM, Nie FQ, Kong R,
Yang JS, Xia R, Xu TP, Jin FY, Liu ZJ, et al: Downregulation of
BRAF activated non-coding RNA is associated with poor prognosis for
non-small cell lung cancer and promotes metastasis by affecting
epithelial-mesenchymal transition. Mol Cancer. 13:682014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li R, Zhang L, Jia L, Duan Y, Li Y, Bao L
and Sha N: Long non-coding RNA BANCR promotes proliferation in
malignant melanoma by regulating MAPK pathway activation. PLoS One.
9:e1008932014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L, Zhang L, Zhang Y and Zhou F:
Increased expression of LncRNA BANCR is associated with clinical
progression and poor prognosis in gastric cancer. Biomed
Pharmacother. 72:109–112. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su S, Gao J, Wang T, Wang J, Li H and Wang
Z: Long non-coding RNA BANCR regulates growth and metastasis and is
associated with poor prognosis in retinoblastoma. Tumour Biol.
36:7205–7211. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang W, Zhang D, Xu B, Wu Z, Liu S, Zhang
L, Tian Y, Han X and Tian D: Long non-coding RNA BANCR promotes
proliferation and migration of lung carcinoma via MAPK pathways.
Biomed Pharmacother. 69:90–95. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zheng JH, Follis Viacava A, Kriwacki RW
and Moldoveanu T: Discoveries and controversies in BCL-2
protein-mediated apoptosis. FEBS J. 283:2690–2700. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brentnall M, Rodriguez-Menocal L, De
Guevara RL, Cepero E and Boise LH: Caspase-9, caspase-3 and
caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell
Biol. 14:322013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo Q, Zhao Y, Chen J, Hu J, Wang S, Zhang
D and Sun Y: BRAF-activated long non-coding RNA contributes to
colorectal cancer migration by inducing epithelial-mesenchymal
transition. Oncol Lett. 8:869–875. 2014.PubMed/NCBI
|
|
28
|
Galuppo R, Ramaiah D, Ponte OM and Gedaly
R: Molecular therapies in hepatocellular carcinoma: What can we
target? Dig Dis Sci. 59:1688–1697. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhou Q, Lui VW and Yeo W: Targeting the
PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol.
7:1149–1167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sicklick JK, Li YX, Jayaraman A, Kannangai
R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS
and Diehl AM: Dysregulation of the Hedgehog pathway in human
hepatocarcinogenesis. Carcinogenesis. 27:748–757. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Delire B and Stärkel P: The Ras/MAPK
pathway and hepatocarcinoma: Pathogenesis and therapeutic
implications. Eur J Clin Invest. 45:609–623. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Neuzillet C, Tijeras-Raballand A, de
Mestier L, Cros J, Faivre S and Raymond E: MEK in cancer and cancer
therapy. Pharmacol Ther. 141:160–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wagner EF and Nebreda AR: Signal
integration by JNK and p38 MAPK pathways in cancer development. Nat
Rev Cancer. 9:537–549. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao JJ, Shi ZY, Xia JF, Inagaki Y and Tang
W: Sorafenib-based combined molecule targeting in treatment of
hepatocellular carcinoma. World J Gastroenterol. 21:12059–12070.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen C and Wang G: Mechanisms of
hepatocellular carcinoma and challenges and opportunities for
molecular targeted therapy. World J Hepatol. 7:1964–1970. 2015.
View Article : Google Scholar : PubMed/NCBI
|
